Cerebrospinal fluid tau, Aβ, and sTREM2 in Former National Football League Players: Modeling the relationship between repetitive head impacts, microglial activation, and neurodegeneration
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Introduction: Cerebrospinal fluid (CSF) protein analysis may facilitate detection and elucidate mechanisms of neurological consequences from repetitive head impacts (RHI), such as chronic traumatic encephalopathy. We examined CSF concentrations of total tau (t‐tau), phosphorylated tau, and amyloid β 1‐42 and their association with RHI in former National Football League (NFL) players. The role of microglial activation (using sTREM2) was examined as a pathogenic mechanism of chronic traumatic encephalopathy. Methods: Sixty‐eight former NFL players and 21 controls underwent lumbar puncture to quantify t‐tau, p‐tau 181, amyloid β 1‐42, and sTREM2 in the CSF using immunoassays. The cumulative head impact index estimated RHI. Results: No between‐group differences for CSF analytes emerged. In the former NFL players, the cumulative head impact index predicted higher t‐tau concentrations (P = .041), and higher sTREM2 levels were associated with higher t‐tau concentrations (P = .009). Discussion: In this sample of former NFL players, greater RHI and increased microglial activation were associated with higher CSF t‐tau concentrations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
TREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020 · cited 1×
“, frontotemporal dementia, AD) [24], with odds ratios for AD risk similar to apolipoprotein E, although the allele frequency in the population is low [25,26].”
Variant of TREM2 Associated with the Risk of Alzheimer's Disease
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558 · cited 1×
“, frontotemporal dementia, AD) [24], with odds ratios for AD risk similar to apolipoprotein E, although the allele frequency in the population is low [25,26].”
The spectrum of disease in chronic traumatic encephalopathy
McKee, A. C., Stein, T. D., Nowinski, C. J., Stern, R. A., Daneshvar, D. H., Alvarez, V. E., Lee, H.-S., Hall, G., Wojtowicz, S. M., Baugh, C. M., et al. (2013) · Brain · doi:10.1093/brain/aws307 · Cited by 2,098
Self-citationCerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Self-citationOlsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049
Self-citationA/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Feldman, H. H., Frisoni, G. B., Hampel, H., Jagust, W. J., Johnson, K. A., Knopman, D. S., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002923 · Cited by 1,864
Self-citationCerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863 · cited 3×
“In vivo fluid biomarkers play a critical role in the clinical diagnosis and study of mechanistic pathways of other neurodegenerative diseases, such as Alzheimer’s disease (AD) [7].”
Self-citationMicroglia and inflammation-mediated neurodegeneration: Multiple triggers with a common mechanism
Block, M. L., & Hong, J.-S. (2005) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.06.004 · Cited by 1,557
The New Neurometabolic Cascade of Concussion
Giza, C. C., & Hovda, D. A. (2014) · Neurosurgery · doi:10.1227/neu.0000000000000505 · Cited by 1,353
TREM2 Maintains Microglial Metabolic Fitness in Alzheimer’s Disease
Ulland, T. K., Song, W. M., Huang, S. C.-C., Ulrich, J. D., Sergushichev, A., Beatty, W. L., Loboda, A. A., Zhou, Y., Cairns, N. J., Kambal, A., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.023 · Cited by 1,263
Clinicopathological evaluation of chronic traumatic encephalopathy in players of American football
Mez, J., Daneshvar, D. H., Kiernan, P. T., Abdolmohammadi, B., Alvarez, V. E., Huber, B. R., Alosco, M. L., Solomon, T. M., Nowinski, C. J., McHale, L., et al. (2017) · JAMA · doi:10.1001/jama.2017.8334 · Cited by 1,098
Self-citationthe TBI/CTE group, McKee, A. C., Cairns, N. J., Dickson, D. W., Folkerth, R. D., Dirk Keene, C., Litvan, I., Perl, D. P., Stein, T. D., Vonsattel, J.-P., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-015-1515-z · Cited by 885 · cited 1×
“The pathognomonic diagnostic lesion of CTE is the perivascular deposition of abnormal phosphorylated tau (p-tau) in neurons and astroglia at the base of the cortical sulci [9].”
Self-citationTREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis
Kleinberger, G., Yamanishi, Y., Suárez-Calvet, M., Czirr, E., Lohmann, E., Cuyvers, E., Struyfs, H., Pettkus, N., Wenninger-Weinzierl, A., Mazaheri, F., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009093 · Cited by 798 · cited 5×
“[33] The antibodies validated in the study by Kleinberger et al.”
InfluentialSelf-citationTREM2 Is a Receptor for β-Amyloid that Mediates Microglial Function
Zhao, Y., Wu, X., Li, X., Jiang, L.-L., Gui, X., Liu, Y., Sun, Y., Zhu, B., Piña-Crespo, J. C., Zhang, M., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.01.031 · Cited by 763
Kitazawa, M., Oddo, S., Yamasaki, T. R., Green, K. N., & LaFerla, F. M. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2868-05.2005 · Cited by 697
Clinical presentation of chronic traumatic encephalopathy
Stern, R. A., Daneshvar, D. H., Baugh, C. M., Seichepine, D. R., Montenigro, P. H., Riley, D. O., Fritts, N. G., Stamm, J. M., Robbins, C. A., McHale, L., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182a55f7f · Cited by 564
Self-citationLi, Y., Liu, L., Barger, S. W., & Griffin, W. S. T. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-05-01605.2003 · Cited by 563
Suárez‐Calvet, M., Kleinberger, G., Araque Caballero, M. Á., Brendel, M., Rominger, A., Alcolea, D., Fortea, J., Lleó, A., Blesa, R., Gispert, J. D., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201506123 · Cited by 522
Self-citationTransient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke
Hesse, C., Rosengren, L., Andreasen, N., Davidsson, P., Vanderstichele, H., Vanmechelen, E., & Blennow, K. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01697-9 · Cited by 450
Self-citationAntibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy
Kondo, A., Shahpasand, K., Mannix, R., Qiu, J., Moncaster, J., Chen, C.-H., Yao, Y., Lin, Y.-M., Driver, J. A., Sun, Y., et al. (2015) · Nature · doi:10.1038/nature14658 · Cited by 445
Self-citationHampel, H., Buerger, K., Zinkowski, R., Teipel, S. J., Goernitz, A., Andreasen, N., Sjoegren, M., DeBernardis, J., Kerkman, D., Ishiguro, K., et al. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.1.95 · Cited by 434
Self-citationTREM2 in Neurodegenerative Diseases
Jay, T. R., von Saucken, V. E., & Landreth, G. E. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0197-5 · Cited by 427 · cited 2×
“sTREM2 is believed to reflect microglial activation, but the exact biological role(s) of sTREM2 remains unclear [24].”
Lee, C. Y. D., Daggett, A., Gu, X., Jiang, L.-L., Langfelder, P., Li, X., Wang, N., Zhao, Y., Park, C. S., Cooper, Y., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.02.002 · Cited by 396
Montenigro, P. H., Baugh, C. M., Daneshvar, D. H., Mez, J., Budson, A. E., Au, R., Katz, D. I., Cantu, R. C., & Stern, R. A. (2014) · Alzheimer's Research & Therapy · doi:10.1186/s13195-014-0068-z · Cited by 375 · cited 2×
“T-tau and sTREM2 were not associated with clinical function, and higher p-tau181 levels were only associated with greater symptoms of depression (a core clinical feature of CTE) [42].”
Self-citationCerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status
Piccio, L., Deming, Y., Del-Águila, J. L., Ghezzi, L., Holtzman, D. M., Fagan, A. M., Fenoglio, C., Galimberti, D., Borroni, B., & Cruchaga, C. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1533-5 · Cited by 337 · cited 1×
“AD cohorts have exhibited elevated [27,32], reduced [33], or normal levels [34] of sTREM2.”
Uryu, K., Laurer, H., McIntosh, T., Praticò, D., Martinez, D., Leight, S., Lee, V. M.-Y., & Trojanowski, J. Q. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-02-00446.2002 · Cited by 337
Self-citationChronic traumatic encephalopathy pathology in a neurodegenerative disorders brain bank
Bieniek, K. F., Ross, O. A., Cormier, K. A., Walton, R. L., Soto-Ortolaza, A., Johnston, A. E., DeSaro, P., Boylan, K. B., Graff-Radford, N. R., Wszolek, Z. K., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1502-4 · Cited by 323
Self-citationIncreased cerebrospinal fluid soluble TREM2 concentration in Alzheimer’s disease
Heslegrave, A., Heywood, W., Paterson, R., Magdalinou, N., Svensson, J., Johansson, P., Öhrfelt, A., Blennow, K., Hardy, J., Schott, J., et al. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0071-x · Cited by 303 · cited 3×
“CSF sTREM2 has been the focus of several recent clinical research studies of AD. sTREM2 correlates with CSF markers of AD t-tau, p-tau [27–29,32], as well as with CSF glial protein YKL-40 [27,28]. sTREM2 concentrations, however, vary with disease progression.”
Self-citationLPS- induced inflammation exacerbates phospho-tau pathology in rTg4510 mice
Lee, D. C., Rizer, J., Selenica, M.-L. B., Reid, P., Kraft, C., Johnson, A., Blair, L., Gordon, M. N., Dickey, C. A., & Morgan, D. (2010) · Journal of Neuroinflammation · doi:10.1186/1742-2094-7-56 · Cited by 293
Beta-amyloid deposition in chronic traumatic encephalopathy
Stein, T. D., Montenigro, P. H., Alvarez, V. E., Xia, W., Crary, J. F., Tripodis, Y., Daneshvar, D. H., Mez, J., Solomon, T., Meng, G., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1435-y · Cited by 291 · cited 3×
“Ab plaques are not a diagnostic neuropathological feature of CTE and, if present, the plaques are often sparse and diffuse, strongly associated with older age, and accelerate the clinical and pathological course of CTE [3,4,10].”
Self-citationSuárez-Calvet, M., Araque Caballero, M. Á., Kleinberger, G., Bateman, R. J., Fagan, A. M., Morris, J. C., Levin, J., Danek, A., Ewers, M., Haass, C., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aag1767 · Cited by 272 · cited 3×
“When disease stage is considered, sTREM2 levels are higher in the early stages of the AD continuum [28,29,33] and can be increased 5 years before symptom onset [35].”
Stern, R. A., Tripodis, Y., Baugh, C. M., Fritts, N. G., Martin, B. M., Chaisson, C., Cantu, R. C., Joyce, J. A., Shah, S., Ikezu, T., et al. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-151028 · Cited by 155
Self-citationTREM2 is associated with increased risk for Alzheimer’s disease in African Americans
Jin, S. C., Carrasquillo, M. M., Benitez, B. A., Skorupa, T., Carrell, D., Patel, D., Lincoln, S., Krishnan, S., Kachadoorian, M., Reitz, C., et al. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0016-9 · Cited by 153 · cited 1×
“There appears to be different TREM2 coding variants that confer risk for AD in African-Americans versus Caucasians [66].”
Petraglia, A., Plog, B., Dayawansa, S., Dashnaw, M., Czerniecka, K., Walker, C., Chen, M., Hyrien, O., Iliff, J., Deane, R., et al. (2014) · Surgical Neurology International · doi:10.4103/2152-7806.147566 · Cited by 151
Smith, D. H., Nakamura, M., McIntosh, T. K., Wang, J., Rodríguez, A., Chen, X.-H., Raghupathi, R., Saatman, K. E., Clemens, J., Schmidt, M. L., et al. (1998) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65643-x · Cited by 143
Self-citationReduced CSF p-Tau 181 to Tau ratio is a biomarker for FTLD-TDP
Hu, W. T., Watts, K., Grossman, M., Glass, J., Lah, J. J., Hales, C., Shelnutt, M., Van Deerlin, V., Trojanowski, J. Q., & Levey, A. I. (2013) · Neurology · doi:10.1212/01.wnl.0000436625.63650.27 · Cited by 113
Self-citationPhosphorylated Tau as a Candidate Biomarker for Amyotrophic Lateral Sclerosis
Grossman, M., Elman, L., McCluskey, L., McMillan, C. T., Boller, A., Powers, J., Rascovsky, K., Hu, W., Shaw, L., Irwin, D. J., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.6064 · Cited by 94
Self-citationBrain Trauma in Aged Transgenic Mice Induces Regression of Established Aβ Deposits
Nakagawa, Y., Reed, L., Nakamura, M., McIntosh, T. K., Smith, D. H., Saatman, K. E., Raghupathi, R., Clemens, J., Saido, T. C., Lee, V. M.-Y., et al. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7375 · Cited by 91
Self-citationSpiegel, J., Pirraglia, E., Osorio, R. S., Glodzik, L., Li, Y., Tsui, W., Saint Louis, L. A., Randall, C., Butler, T., Xu, J., et al. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-150167 · Cited by 45 · cited 1×
“Furthermore, although CSF p-tau181 is an established biomarker for neurofibrillary tangle pathology in AD [7] (and frontotemporal lobar degeneration-transactive response DNA-binding protein 43 [48]), p-tau231 has been shown to be superior to p-tau181 in the clinical and neuropathological diagnostic prediction of AD [4…”
Self-citation
Cited by
Katz, D. I., Bernick, C., Dodick, D. W., Mez, J., Mariani, M. L., Adler, C. H., Alosco, M. L., Balcer, L. J., Banks, S. J., Barr, W. B., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000011850 · Cited by 337
Self-citationNowinski, C. J., Bureau, S. C., Buckland, M. E., Curtis, M. A., Daneshvar, D. H., Faull, R. L. M., Grinberg, L. T., Hill-Yardin, E. L., Murray, H. C., Pearce, A. J., et al. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.938163 · Cited by 183
Self-citationSoluble TREM2: Innocent bystander or active player in neurological diseases?
Filipello, F., Goldsbury, C., You, S. F., Locca, A., Karch, C. M., & Piccio, L. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105630 · Cited by 134
Boza-Serrano, A., Vrillon, A., Minta, K., Paulus, A., Camprubí-Ferrer, L., Garcia, M., Andreasson, U., Antonell, A., Wennström, M., Gouras, G., et al. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02469-6 · Cited by 66
Self-citationValera, E. M., Campbell, J., Gill, J., & Iverson, K. M. (2019) · Journal of Aggression, Maltreatment & Trauma · doi:10.1080/10926771.2019.1581864 · Cited by 55
Metadata
- Authors
- Alosco, M. L., Tripodis, Y., Fritts, N. G., Heslegrave, A., Baugh, C. M., Conneely, S., Mariani, M., Martin, B. M., Frank, S., Mez, J., Stein, T. D., Cantu, R. C., McKee, A. C., Shaw, L. M., Trojanowski, J. Q., Blennow, K., Zetterberg, H., & Stern, R. A.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2018-07-23
- Volume
- 14
- Issue
- 9
- Pages
- 1159-1170
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2883556666
- Cited by
- 121
- References
- 39
- FWCI
- 10.40
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.